Autonomix Medical, Inc. (NASDAQ:AMIX) Sees Large Decline in Short Interest

Autonomix Medical, Inc. (NASDAQ:AMIX) saw a significant drop in short interest in August. As of August 31st, there was short interest totaling 58,624 shares, a drop of 46.1% from the August 15th total of 108,801 shares. Based on an average daily volume of 4,225,824 shares, the days-to-cover ratio is currently 0.0 days. Currently, 6.4% of the company’s stock are short sold.

Analysts Set New Price Targets

Several brokerages have recently issued reports on AMIX. Zacks Research upgraded shares of Autonomix Medical to a “hold” rating in a report on Tuesday, June 2nd. Wall Street Zen cut shares of Autonomix Medical from a “sell” rating to a “strong sell” rating in a research report on Monday. Finally, Weiss Ratings raised shares of Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Autonomix Medical presently has a consensus rating of “Hold” and a consensus target price of $42.00.

Autonomix Medical Stock Down 2.8%

NASDAQ:AMIX traded down $0.12 during mid-day trading on Tuesday, reaching $4.21. 127,436 shares of the stock were exchanged, compared to its average volume of 1,643,072. The stock has a market capitalization of $4.09 million, a P/E ratio of -0.10 and a beta of -1.00. Autonomix Medical has a 1 year low of $2.44 and a 1 year high of $32.55. The company has a 50 day simple moving average of $5.87 and a 200-day simple moving average of $7.29.

Autonomix Medical (NASDAQ:AMIX) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($5.02) earnings per share for the quarter, beating the consensus estimate of ($6.40) by $1.38. As a group, research analysts predict that Autonomix Medical will post -20.17 EPS for the current year.

About Autonomix Medical

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.